Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia

References

• Hug V, Keating M, McCredie K, Hester J, Bodey G P, Freireich E J. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 1983; 52: 773–779
   PubMed Web of Science ®Google Scholar
• Rees J KH, Gray R G, Swirsky D, Hayhoe F GJ. Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial. Lancet 1986; 2: 1236–1241
   PubMed Web of Science ®Google Scholar
• Dutcher J P, Schiffer C A, Wiernik P H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration, and survival. J Clin Oncol 1987; 5: 1364–1372
   PubMed Web of Science ®Google Scholar
• Estey E, Smith T L, Keating M J, McCredie K B, Gehan E A, Freireich E J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257–263
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393
   PubMed Web of Science ®Google Scholar
• Thiebaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79: 501–506
   PubMed Web of Science ®Google Scholar
• Tavernier E, Le Q H, Elhamri M, Thomas X. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 2003; 27: 205–214
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk R F, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380
   PubMed Web of Science ®Google Scholar
• Ventura G J, Hester J P, Smith T L, Keating M J. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988; 27: 34–37
   PubMed Web of Science ®Google Scholar
• Swirsky D M, de Bastos M, Parish S E, Rees J KH, Hayhoe F GJ. Features affecting outcome during remission induction of acute myeloid leukemia in 619 adult patients. Br J Haematol 1986; 64: 435
   PubMed Web of Science ®Google Scholar
• Visani G, Bernasconi P, Boni M, Castoldi G L, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of inductioin/consolidation therapy in influencing the outcome of acute myeloid leukemia—analysis of 848 patients. Leukemia 2001; 15: 903–909
   PubMed Web of Science ®Google Scholar
• Bunin N J, Pui C H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 1590–1595
   PubMed Web of Science ®Google Scholar
• Vernant J P, Brun B, Mannoni P, Dreyfus B. Respiratory distress of hyperleukocytic granulocytic leukemias. Cancer 1979; 44: 264–268
   PubMed Web of Science ®Google Scholar
• Lester T J, Johnson J W, Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med 1985; 79: 43–48
   PubMed Web of Science ®Google Scholar
• Porcu P, Danielson C F, Orazi A, Heerema N A, Gabig T G, McCarthy L J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997; 98: 433–436
   PubMed Web of Science ®Google Scholar
• Estey E. Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol 2001; 38: 32–37
   PubMed Web of Science ®Google Scholar
• Giles F J, Shen Y, Kantarjian H M, Korbling M J, O'Brien S, Anderlini P, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 2001; 42: 67–73
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D AG, Gralnick H R, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• ISCN. An international system for human cytogenetic nomenclature. Karger, Basel 1995
   Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Seftel M D, Bruyere H, Copland M, Hogge D E, Horsman D E, Nantel S H, et al. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). Eur J Haematol 2002; 69: 193–199
   PubMed Web of Science ®Google Scholar
• Hosmer D W, Lemeshow S. Applied Logistic regression. John Wiley, New York 1989
   Google Scholar
• Cox D R. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187–220
   Web of Science ®Google Scholar
• Metz C E. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283–298
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104: 2467–2474
   PubMed Web of Science ®Google Scholar
• Hofmann W K, Heil G, Zander C, Wiebe S, Ottmann O G, Bergmann L, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004; 83: 498–503
   PubMed Web of Science ®Google Scholar
• Nowacki P, Zdziarska B, Fryze C, Urasinski I. Co-existence of thrombocytopenia and hyperleukocytosis (‘critical period’) as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias. Haematologia (Budap) 2002; 31: 347–355
   PubMedGoogle Scholar
• Kiyoi K, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 1997; 11: 1447–1452
   PubMed Web of Science ®Google Scholar
• Kottaridis P D, Gale R E, Frew M E, Harrison G, Langabeer S E, Belton A A, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutation in acute myeloid leukemia. Blood 1999; 93: 3074–3080
   PubMed Web of Science ®Google Scholar
• Wahlin A, Markevarn B, Golovleva I, Nilsson M. Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Haematol 2002; 68: 54–63
   PubMed Web of Science ®Google Scholar